AC Immune (ACIU) Current Deferred Revenue: 2014-2024
Historic Current Deferred Revenue for AC Immune (ACIU) over the last 9 years, with Dec 2024 value amounting to $97.1 million.
- AC Immune's Current Deferred Revenue rose 62409240.74% to $97.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $97.1 million, marking a year-over-year increase of 62409240.74%. This contributed to the annual value of $97.1 million for FY2024, which is 62309.34% up from last year.
- As of Q4 2024, AC Immune's Current Deferred Revenue stood at $97.1 million, which was up 525,657.37% from $18,467 recorded in Q3 2024.
- In the past 5 years, AC Immune's Current Deferred Revenue registered a high of $102.9 million during Q1 2021, and its lowest value of $155.57 during Q4 2023.
- In the last 3 years, AC Immune's Current Deferred Revenue had a median value of $411,971 in 2022 and averaged $8.4 million.
- Per our database at Business Quant, AC Immune's Current Deferred Revenue plummeted by 99.97% in 2023 and then surged by 62,409,240.74% in 2024.
- AC Immune's Current Deferred Revenue (Quarterly) stood at $338,484 in 2020, then spiked by 129.73% to $777,588 in 2021, then fell by 21.64% to $609,319 in 2022, then tumbled by 99.97% to $155.57 in 2023, then surged by 62,409,240.74% to $97.1 million in 2024.
- Its Current Deferred Revenue was $97.1 million in Q4 2024, compared to $18,467 in Q3 2024 and $49,761 in Q2 2024.